ALSO IN THIS MONTH'S ISSUE

• The Rise Of Computational Biology In Biopharma

  I thought I’d peel a layer off the onion to reveal a trend that’s gaining momentum and having a positive impact during a somewhat negative biopharma news cycle: computational biology.

• How To Reduce COGS & Expedite Commercial-Scale CGT Manufacturing

  Industry luminaries from Kite Pharma, Novartis Gene Therapies, and SwanBio share their knowledge on why the road to cost-efficient and timely commercial manufacturing for cell and gene therapies (CGTs) is paved with AI, automation, clinical trial design, AAV vector efficiencies, skilled team members, and more.

• How Are DCTs Impacting Your Clinical Sites?

  Where do your sites stand on DCTs? For this article, we spoke with three site experts who discussed the pain points of DCTs, including costs, budgeting, training, support, staffing, resources, and more.

• Building New Solutions For 2023 In Manufacturing And Supply Chain

  In this Q&A, 10 executives provide their thoughts on what the future holds for biopharmaceutical manufacturing and supply chain operations, and which issues will have the most impact.

• A More Balanced And Stable Future With CDMOs

  Two Industry Experts talk about where they see the outsourcing industry going in the near future.